alexa
Reach Us +1 702 553-3066
Nano Anti-cancer Drugs: Future Magic Medication | 25432
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Nano anti-cancer drugs: Future magic medication

2nd World Congress on Cancer Science & Therapy

Imran Ali

ScientificTracks Abstracts: JCST

DOI: 10.4172/1948-5956.S1.021

Abstract
Routine chemotherapy for cancer treatment has several side and toxic effects. Recently, a new approach of nano anti-cancer drug has been developed and only few drugs are available in the market today. The unique features of these drugs are targeted action on cancer cells only without any side effect and, hence, called magic drugs. The important molecules used for preparation of nano anti-cancer drugs are cisplatin, carboplatin, bleomycin, 5-fluorouracil, doxorubicin, dactinomycin, 6-mercaptopurine, paclitaxel, topotecan, vinblastin and etoposide etc. The most commonly used materials for preparing nano particles carriers are dendrimers, polymeric, liposomal, micelles inorganic, organic etc. The proposed lecture will comprise the-of-art of nano drugs in cancer chemo-therapy including preparation, types of drugs, mechanism, future perspectives etc.
Biography
Dr. Imran Ali has completed his Ph.D. at the age of 27 years from Indian Institute of Technology, Roorkee, India. He has enjoyed various positions in abroad. Dr. Imran Ali is an academician and researcher of International repute. He has published five books from Taylor & Francis, USA; John Wiley & Sons, USA; Marcel Dekker, Inc., USA; John Wiley & Sons, UK and Elsevier, The Netherlands publishers. He has authored more than 250 publications with 2,700 Scopus citations. He is Editor of ScienceJet Journal and on editorial boards of 10 Scientific Journals.
Top